In H292 xenografts with inducible GPX4 loss, daily intraperitoneal DHA at 5 mg/kg augmented tumor growth suppression relative to either intervention alone. Liproxstatin-1 partially reversed the effect, supporting a ferroptosis contribution in this engineered mouse model. [2]
In a separate CT26 mouse xenograft study, DHA at 50 mg/kg on Days 7, 9 and 11 did not significantly lower final tumor weight versus control. Adding DHA to three 6-Gy radiotherapy fractions did not significantly improve tumor weight versus radiotherapy alone. These negative findings apply to the tested regimen. [3]
DHA augments GPX4-loss-associated growth suppression in H292 xenografts
Animal study · Human H292 tumors carrying doxycycline-inducible GPX4 knockout in 6–8-week-old female athymic nude mice [2]
DHA plus doxycycline-induced GPX4 loss retarded tumor growth more than either intervention alone; liproxstatin-1 partially restored growth. The combination also lowered Ki67 staining. The result supports sensitization in this engineered model.
Conditions shared by the study groups
- Route
- Intraperitoneal injections; diet for doxycycline
- Frequency
- Daily injections
- Treatment course
- Two weeks
- Vehicle
- Vehicle identity discrepant: saline in Methods, PBS in caption
- Vehicle and normal diet
- Model: H292 inducible-GPX4-knockout xenografts; Normal diet
- Reported limits: Sample size and doxycycline diet content not specified in read text/caption.
- DHA and normal diet
- Model: H292 inducible-GPX4-knockout xenografts; Normal diet
- Reported limits: Sample size and doxycycline diet content not specified in read text/caption.
- Induced GPX4 loss
- Model: H292 inducible-GPX4-knockout xenografts; Doxycycline diet
- Reported limits: Sample size and doxycycline diet content not specified in read text/caption.
- DHA plus induced GPX4 loss
- Model: H292 inducible-GPX4-knockout xenografts; Doxycycline diet
- Reported limits: Sample size and doxycycline diet content not specified in read text/caption.
- Liproxstatin-1 rescue
- Model: H292 inducible-GPX4-knockout xenografts; Doxycycline diet
- Reported limits: Sample size and doxycycline diet content not specified in read text/caption.
Methods and source locations
Compound reported in the paper: Dihydroartemisinin; Compound label in the paper: DAT
Compound-level findings in the reported models. No validation of current A10310 lots or equivalence of suppliers; no clinical efficacy inference.
Figure 6E–G; Results: DAT sensitizes cancer cells to ferroptosis – therapeutic potential; Methods: In vivo xenograft studies
Xenograft tumor growth: Daily caliper tumor-volume measurement; error bars standard error; no exact effect size extracted — Figure 6E–F and associated Results; In vivo xenograft studies
Tumor Ki67 and GPX4 staining: Tumor immunohistochemistry; qualitative comparison — Figure 6G and associated Results
Vehicle and normal diet · In vivo xenograft studies; Figure 6E–G
DHA and normal diet · In vivo xenograft studies; Figure 6E–G
Induced GPX4 loss · In vivo xenograft studies; Figure 6E–G
DHA plus induced GPX4 loss · In vivo xenograft studies; Figure 6E–G
Liproxstatin-1 rescue · In vivo xenograft studies; Figure 6E–G
No detectable additional benefit from DHA with hypofractionated radiotherapy
Animal study · CT26 colorectal tumor xenografts in female BALB/c nude mice, 6–8 weeks old; randomized, n=6 per group [3]
DHA alone did not significantly reduce final tumor weight relative to PBS control. RT and DHA+RT reduced tumor weight relative to control, but adding DHA did not significantly improve tumor weight over RT alone under this regimen. Non-significance does not demonstrate equivalence or exclude benefit under other conditions.
Conditions shared by the study groups
- Vehicle
- PBS control; DHA formulation unspecified
- PBS control
- Model: CT26 xenografts; female BALB/c nude mice; n=6/group
- Route: Abdominal injection
- Frequency: Comparator schedule; control injection frequency not separately explicit in prose
- Treatment course: Day 15 tumor collection
- Reported limits: No exact mean/SEM adopted because abstract and Table 1 differ.
- DHA alone
- Model: CT26 xenografts; female BALB/c nude mice; n=6/group
- Route: Abdominal injection
- Frequency: Days 7, 9 and 11
- Treatment course: 3 injections; Day 15 tumor collection
- Reported limits: No exact mean/SEM adopted because abstract and Table 1 differ.
- RT alone
- Model: CT26 xenografts; female BALB/c nude mice; n=6/group
- Route: Tumor-directed irradiation
- Frequency: Days 7, 9 and 11
- Treatment course: 3 fractions; Day 15 tumor collection
- Reported limits: No exact mean/SEM adopted because abstract and Table 1 differ.
- DHA plus RT
- Model: CT26 xenografts; female BALB/c nude mice; n=6/group
- Route: Abdominal DHA injection; tumor-directed irradiation
- Frequency: Days 7, 9 and 11; DHA 1 h before RT
- Treatment course: 3 combined treatments; Day 15 tumor collection
- Reported limits: No exact mean/SEM adopted because abstract and Table 1 differ.
Methods and source locations
Compound reported in the paper: Dihydroartemisinin; Compound label in the paper: DHA
Compound-level findings in the reported models. No validation of current A10310 lots or equivalence of suppliers; no clinical efficacy inference.
Methods 2.1–2.4; Results and Table 1; Figure 3; Discussion
Final tumor weight between treatment groups: Resected tumor weight on Day 15; Table 1 specifies mean ± SEM, n=6/group; no conflicting mean/SEM adopted — Table 1; Results; Figure 3
PBS control · Methods 2.1–2.4; Table 1; Figure 3
DHA alone · Methods 2.1–2.4; Table 1; Figure 3
RT alone · Methods 2.1–2.4; Table 1; Figure 3
DHA plus RT · Methods 2.1–2.4; Table 1; Figure 3